Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple MyelomaZacks Investment Research • 09/23/24
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplantGlobeNewsWire • 09/20/24
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year oldGlobeNewsWire • 09/20/24
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 studyGlobeNewsWire • 09/20/24
Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDAPRNewsWire • 09/16/24
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancersGlobeNewsWire • 09/12/24
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study GoalsZacks Investment Research • 09/11/24
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSUGlobeNewsWire • 09/11/24
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal studyGlobeNewsWire • 09/11/24
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two OthersZacks Investment Research • 09/02/24
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosisGlobeNewsWire • 09/02/24
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplantGlobeNewsWire • 08/08/24